Combining Rybelsus with a balanced diet and regular exercise can further enhance weight loss outcomes

Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Lymphadenopathy is not listed in the Summary of Product Characteristics or reported in SURPASS or SURMOUNT clinical trials Common Mounjaro side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and reduced appetite Lymph node swelling during treatment may result from infections, vaccinations, local inflammation, or other unrelated conditions Persistent, enlarging, or hard lymph nodes require GP evaluation to exclude serious underlying causes including malignancy Report any suspected adverse effects through the MHRA Yellow Card Scheme for ongoing pharmacovigilance monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus

13 In many cases, a combination of weight loss medications, including medications like GLP-1s, and CPAP therapy may provide the greatest benefit
If you do not have the traditional indications for a GLP, microdosing may be an option